Rani Therapeutics Holdings, Inc reports results for the quarter ended September 30 - Earnings Summary

Rani Therapeutics Holdings

09/11/2026 22:02

Rani Therapeutics Holdings, Inc RANI.OQ reported a quarterly adjusted loss of 4 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -12 cents.  The mean expectation of four analysts for the quarter was for a loss of 5 cents per share. Wall Street expected results to range from -5 cents to -4 cents per share.
Revenue was $1.71 million​; analysts expected $1.28 million. 
Rani Therapeutics Holdings, Inc's reported EPS for the quarter was a loss of 4 cents​.
The company reported a quarterly loss of $7.73 million.
Rani Therapeutics Holdings, Inc shares had fallen by 30.9% this quarter and lost 59.5% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 5% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Rani Therapeutics Holdings, Inc is $5.50, about 90.1% above its last closing price of $0.55
This summary was machine generated from LSEG data November 9 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.05
-0.04
Beat
Jun. 30 2026 
-0.05
-0.04
Beat
Mar. 31 2026 
-0.04
-0.04
Met
Dec. 31 2025 
-0.07
-0.07
Met